VTVT Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
-100.0%
36.8M
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
-100.0%
36.8M
0
0
Operating Expenses
12.4M
-10.8%
13.9M
+2.6%
13.6M
+69.3%
8.0M
-25.0%
10.7M
R&D
7.5M
-14.1%
8.8M
-2.3%
9.0M
+129.7%
3.9M
-44.3%
7.0M
SG&A
4.9M
-5.1%
5.2M
+12.2%
4.6M
+15.6%
4.0M
+8.1%
3.7M
Operating Income
-12426000
+10.8%
-13930000
-159.9%
23.3M
+390.0%
-8021000
+25.0%
-10699000
EBITDA
-12425000
+10.8%
-13929000
-159.9%
23.3M
+390.1%
-8019000
+25.0%
-10697000
Net Income
-11620000
+11.0%
-13054000
-154.1%
24.1M
+438.1%
-7138000
+31.0%
-10345000
EPS (Basic)
$-0.94
+10.5%
$-1.05
-154.1%
$1.94
+440.4%
$-0.57
+47.2%
$-1.08
EPS (Diluted)
$-0.94
+10.5%
$-1.05
-163.6%
$1.65
+389.5%
$-0.57
+47.2%
$-1.08
Shares (Diluted)
12.4M
+0.1%
12.4M
-15.2%
14.6M
+17.4%
12.5M
+54.8%
8.1M
vTv Therapeutics (VTVT) — Financials